Millennium Management’s Tarsus Pharmaceuticals TARS Stock Holding History

Millennium Management’s Portfolio TARS Stock Details TARS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.89M	Hold	30,000	–	–	﹤0.01%	3866
2026 Q1	$2.1M	Buy	30,000 +10,000	+50%	+$699K	﹤0.01%	3831
2025 Q4	$1.64M	Buy	+20,000	New	+$1.49M	﹤0.01%	4105

Other funds holding TARS

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Jupiter Topco New York $245B AUM

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Millennium Management's TARS Position: Q2 2026 in Review

Millennium Management increased its Tarsus Pharmaceuticals (TARS) stake by 153% in Q2 2026, buying an estimated $55.1M and bringing the position to 1,427,124 shares worth $89.8M. The position accounts for 0.03% of the portfolio, ranked #556.

Millennium Management first reported a position in TARS in Q4 2020 and has held it in 16 quarters since. 256 funds tracked by Wall St. Rank hold TARS as of Q2 2026.

Millennium Management held 1,427,124 shares of Tarsus Pharmaceuticals worth $89.8M as of Q2 2026.
Millennium Management bought 862,545 Tarsus Pharmaceuticals shares in Q2 2026, an estimated $55.1M.
Tarsus Pharmaceuticals made up 0.03% of Millennium Management's portfolio in Q2 2026, its #556 holding.
Millennium Management first reported a position in Tarsus Pharmaceuticals in Q4 2020 and has held it in 16 quarters since.
256 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.